2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

653. Multiple Myeloma: Clinical and Epidemiological: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Omics Technologies, Pathology, Serologic Tests, Treatment Considerations, Combination Therapy, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Radiation Therapy, Workforce, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Bleeding and Clotting, Thromboembolism, Immunology, Immunodeficiency, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

2231 Responses after limited duration bispecific antibody therapy in patients with relapsed refractory multiple myeloma: A single institution experience

Michael Sandhu, MD, Sidharth Srinivasan2, Buse Eglenen Polat, MD3, Ioannis Mantzaris, MD, MS4, Aditi Shastri, MD5, Marina Konopleva, MD, PhD6, Ridhi Gupta, MD7, Mendel Goldfinger, MD8, Lauren C. Shapiro, MD9, Noah Kornblum, MD10, Kira Gritsman, MD, PhD11, Eric Feldman, MD12, Dennis Cooper, MD13, R. Alejandro Sica, MD14, Shyamala Navada, MD15, Vincent Rella, MD16, Amit Verma, MD17, David Levitz, MD18
1 Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, United States
2 Montefiore Medical Center, Bronx, New York, United States
3 Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, United States
4 Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, United States
5 Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, United States
6 Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, United States
7 Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, United States
8 Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, United States
9 Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, United States
10 Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, United States
11 Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, United States
12 Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, United States
13 Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, United States
14 Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, United States
15 Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, United States
16 Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, United States
17 Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, United States
18 Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, United States

Background:

Bispecific antibodies (bsAb) targeting BMCA and GPRC5D have become standard of care for relapsed/refractory multiple myeloma (MM). BsAb therapy is given continuously in the R/R setting until intolerance or disease progression. Uninterrupted therapy leads to prolonged immunosuppression and predisposition to infections, as well as other cumulative treatment toxicities such as dysgeusia and cutaneous toxicities for GPRC5D directed therapy. Consequently, patients often discontinue therapy, and the impact of treatment discontinuation on efficacy remains currently unclear.

We evaluated the progression-free survival (PFS) of patients who discontinue treatment with bsAb after less than 9 months of therapy. We present a single-institution experience of patients with R/R myeloma receiving <9 months of bsAb therapy.

Methods:

We performed a retrospective review of patients at Montefiore Medical Center from 2016 to 2026. All patients who received at least one dose of Teclistamab, Talquetamab, or Elranatamab were screened. Patients who stopped therapy at <9 months were included in analysis. Patients were excluded if they had less than 2 months follow-up after stopping bsAb, were primary refractory, relapsed at time of discontinuation, or proceeded to next line of therapy while in remission including maintenance therapy with alternative drug.  The primary outcome was PFS, with secondary outcomes including time to progression, overall response rate, safety and reason for discontinuation of therapy.

Results:

102 patients were screened, 11 met inclusion criteria. The median age was 70 years, with 2:1 male/female. Median prior lines of therapy was 6, and 91% were triple-class refractory disease. Eight patients received teclistamab, and three received talquetamab. The median duration of bsAb therapy was 148 days (range 21-267 days). Reasons for discontinuing therapy included infection (6), pericardial effusion (1), rash (2), and patient decision (2). At the time of discontinuation, 55% of patients had been hospitalized for any reason while at therapy.

At the time of discontinuation, 3 patients achieved PR, 6 patients achieved VGPR and 2 patients had uCR. The median time to best response was 36 days. Eight patients (73%) remained in response with a median of 10 months of follow-up off therapy (time off treatment 49-874 days). All three patients who had relapsed were in PR at end of therapy. Of the patients who progressed, there was no significant difference in median age, lines of therapy, or reported cytogenetics. One patient who progressed had extramedullary disease (EMD), whereas 0/8 patients who remained in durable remission had EMD. 2/3 of the patients who progressed had received Talquetamab with a median duration of maintained response of 50 days (range 49-137).

Conclusion:

Limited duration bsAb was feasible in this small cohort of heavily pretreated patients with R/R MM. The majority of patients remained in remission at last follow-up with durability projected to be at least similar to findings in Majestec1 at a median of 10 months follow-up.

Infection was the leading cause of treatment discontinuation. Although supportive measures can mitigate infection risk, continuous bsAb therapy remains associated with frequent infections and hospitalizations, supporting limited-duration therapy as a potential strategy to reduce toxicity.

Our data suggests that patients achieving deep and early responses to bsAb therapy may remain in remission after treatment discontinuation even after <6 months of therapy. As far as we are aware, this cohort represents the shortest time on therapy with other retrospective publications having a median of >7 months (Chakraborty, 2024), and the upcoming prospective LimiTec trial requiring 6-9 months of therapy.  Data supporting treatment discontinuation strategies for bsAb in MM are developing, and our study emphasizes the need to define the role of limited duration therapy based on depth of response rather than a one-size-fits-all fixed duration. 

 

Michael Sandhu, MD: No relevant conflicts of interest to declare.